TVAX cancer vaccine - TVAX Biomedical

Drug Profile

TVAX cancer vaccine - TVAX Biomedical

Alternative Names: TVI-Brain-1; TVI-Breast-1; TVI-Colon-1; TVI-Kidney-1; TVI-Leukemia-1; TVI-Lung-1; TVI-Melanoma-1; TVI-Ovary-1; TVI-Pancreas-1; TVI-Prostate-1

Latest Information Update: 02 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TVAX Biomedical
  • Class Cancer vaccines; Cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - CNS cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Brain cancer; Glioma; Renal cell carcinoma
  • Phase I/II Breast cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Prostate cancer

Most Recent Events

  • 10 Oct 2016 TVAX cancer vaccine is still in phase II and phase I/II trials for various cancer indications in the US (TVAX Biomedical pipeline, October 2016)
  • 10 Oct 2016 Phase-II clinical trials in Brain cancer in USA (IV) before October 2016 (TVAX Biomedical pipeline, October 2016)
  • 19 Aug 2015 No recent reports on development identified - Phase-I/II for Breast cancer, Colorectal cancer, Leukaemia, Lung cancer, Malignant melanoma, Ovarian cancer, Pancreatic cancer, Prostate cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top